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Background and purpose: Approximately 9000 people in the UK are aﬀected by
Huntington’s disease (HD). People with HD require ongoing health and social
care support. There is a knowledge gap about costs of health and social care use
associated with HD in the UK. This paper estimates the economic cost in the UK.
Methods: Data on UK patients for the year 2013 were extracted from the
European Huntington’s Disease Network REGISTRY study, a full clinical
dataset, including the full medical history and medication history for patients
with HD. National unit costs for the price year 2013 were applied to health
and social care services.
Results: Data were available for 131 people. The mean annual cost per per-
son with HD was £21 605. The largest proportion of this cost (65%) was due
to informal care (£14 085).
Conclusions: Informal care was the largest driver of costs across all stages of
HD; thus there is a need to also consider the needs of carers when planning
services for people with HD.
Introduction
Huntington’s disease (HD) is an inherited neurological
disease, characterized by a progressive deterioration of
movement, cognition and behaviour. Approximately
12 in every 100 000 people in the UK are aﬀected by
HD [1]. Research has been conducted into the eco-
nomic cost of other neurodegenerative conditions
[2,3]. A European study of service use associated with
HD has been undertaken [4], but costs were not esti-
mated. One US study of the cost of HD was identiﬁed
[5]. An estimate of the economic cost of HD in the
UK is presented.
Methods
Data
The European Huntington’s Disease Network (EHDN)
REGISTRY database [6] includes demographics,
medical history and longitudinal information on
patients with HD across Europe. Health and social care
use is recorded using a Client Service Receipt Inven-
tory. It contains information on hospital and residen-
tial services, primary and community care, diagnostic
tests, informal care, aids and adaptations to the home.
Patients enrolled in the EHDN REGISTRY obser-
vational study provide informed, written consent for
their anonymized data to be used for research pur-
poses. Ethical approval was obtained from Bangor
University School of Healthcare Sciences Ethics Com-
mittee (ref. 2015-15652). Data for UK patients from 1
January 2013 to 31 December 2013 were analysed.
Patients were categorized by total functional capacity
(TFC) score. A TFC score of 11–13 is classiﬁed as
stage I (earliest), 7–10 is stage II, 3–6 is stage III, 1–2
is stage IV and a score of 0 is stage V (latest).
Costing service use
National unit costs for the price year 2013 were
applied to the service use data by multiplying the fre-
quency of contacts by a unit cost [7–9]. The
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REGISTRY database does not record the length of a
contact; therefore a ﬁxed length was assumed for each
visit, e.g. 12 min for a general practitioner visit. Medi-
cation was costed by multiplying dose and duration of
a medication course by its unit cost [9]. Informal care
included personal care, help inside the home and help
outside the home. The cost of informal care was esti-
mated using the hourly rate of a home care worker as
a replacement service (£24 per hour) [7]. Descriptive
statistics are used to present the mean, standard devia-
tion and median costs of service use, by TFC score.
Results
Client Service Receipt Inventory data were available
for 131 people (10% of REGISTRY patients in 2013).
Our sample contained similar proportions of patients
in each TFC stage compared to the larger REGIS-
TRY sample; however, our sample had no stage V
patients (3% of the REGISTRY sample were stage
V). The mean age was 50 years (range 18–78). The
sample contained 72 females and 59 males.
Health and social care costs
Mean annual costs per person in stage I were £2250,
rising to £89 760 in stage IV. The average cost across
all stages was £21 605 per year (Table 1). This equates
to £195 million per year in the UK.
Discussion
Average US costs have been estimated to be $4947
(£3150 in 2013 pounds) per person with HD in the early
stage rising to $22 582 (£14 378 in 2013 pounds) in the
late stage for commercial patients, and from $3257
(£2074 in 2013 pounds) in early stage Medicaid patients
to $37 495 (£23 873 in 2013 pounds) in late stage Medi-
caid patients [5]. In the US study more Medicaid
patients were in long-term care compared to commercial
patients, thus driving the cost diﬀerences; the authors
noted that this may be due to Medicaid patients being at
a later disease stage or because data on long-term care
for the commercial patients is less complete [5]. In our
study, the average annual cost per person was £21 605,
which is comparable to the cost of dementia in the UK
(£32 242 per person) [10]. Looking at disease severity,
our range was greater than in Divino et al. [5], at £2250
per person in the earliest stage of HD and £89 760 in the
later stages. However, there are substantial diﬀerences
between the US and UK healthcare systems and the cat-
egories of costs included in the respective studies; there-
fore our ﬁndings are only applicable to UK patients. T
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As would be expected with a degenerative condi-
tion, costs increased by disease severity, presenting the
case for investing in care and support for people in
the earlier stages to keep them functioning well. The
appropriate time to introduce and subsequently
increase social care packages to support people with
HD and their informal carers is likely to vary between
individuals, but our study has identiﬁed that increased
social care support is likely to be needed during stages
III and IV of HD. Informal care was the largest dri-
ver of costs; thus there is a need to consider the needs
of carers as well as people with HD. While the study
population was representative of the larger REGIS-
TRY sample in terms of TFC stratiﬁcation, it is not
possible to say whether service use data were missing
at random, and therefore whether there is inherent
bias in our cost estimates due to under-reporting of
service use. In particular, our study had no people in
stage V. REGISTRY data are collected by interviews
in outpatient visits, which may lead to under-represen-
tation of people living in long-term care. As such, the
estimated costs of HD presented here may be even
higher in practice.
Acknowledgements
The South East Wales Trials Unit (SEWTU) is
funded by the Wales Assembly Government through
Health and Care Research Wales. Julia Townson,
Rob Trubey and Vince Poile are acknowledged as
members of the ENGAGE-HD trial management
team. Additionally, we thank all EHDN REGISTRY
Study Group investigators for collecting the data and
all participating REGISTRY patients for their time
and eﬀort. The investigators of the EHDN are listed
in full in Data S1.
This research was carried out as part of ENGAGE-
HD: Supporting activity engagement in people with
Huntington’s disease, which is funded by the National
Institute for Health and Social Care Research (UK)
(grant reference NIHR FS 2012 – Busse-Morris).
Disclosure of conflicts of interest
The authors declare no ﬁnancial or other conﬂicts of
interest.
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Data S1. List of EHDN investigators.
References
1. Evans SJ, Douglas I, Rawlins MD, et al. Prevalence of
adult Huntington’s disease in the UK based on diag-
noses recorded in general practice records. J Neurol
Neurosurg Psychiatry 2013; 84: 1156–1160.
2. Mateus C, Coloma J. Health economics and cost of ill-
ness in Parkinson’s disease. Eur Neurol Rev 2013; 8: 6–
9.
3. Luengo-Fernandez R, Leal J, Gray A. Dementia 2010:
The Economic Burden of Dementia and Associated
Research Funding in the United Kingdom. Alzheimer’s
Research Trust: Cambridge, 2010.
4. Busse M, Al-Madfai H, Kenkre J, et al. Utilisation of
healthcare and associated services in Huntington’s dis-
ease: a data mining study. PLoS Curr 2011; 3. doi:
10.1371/currents.RRN1206.
5. Divino V, DeKoven M, Warner JH, et al. The direct
medical costs of Huntington’s disease by stage. A retro-
spective commercial and Medicaid claims data analysis.
J Med Econ 2013; 16: 1043–1050.
6. Orth M, Handley OJ, Schwenke C, et al. Observing
Huntington’s disease: the European Huntington’s dis-
ease network’s REGISTRY. PLoS Curr 2010; 2. doi:
10.1371/currents.RRN1184.
7. Curtis L. Unit Costs of Health and Social Care. Personal
Social Services Research Unit, University of Kent : Can-
terbury, UK, 2013.
8. Department of Health. NHS Reference Costs 2012–13.
http://data.gov.uk/publisher/nhs-reference-costs-2012-to-
2013 (accessed 06/08/2015)
9. National Health Service: Prescription Cost Analysis 
England, 2013. http://www.hscic.gov.uk/catalogue/
PUB13887 (accessed 25/08/2015)
10. Prince M, Knapp M, Guerchet M, et al. Dementia UK:
Update. Alzheimer’s Society. 2014.
© 2016 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
1590 C. JONES ET AL.
